Back to search results

NT-II™ Collagen for Activity-Related Knee Discomfort

This study is looking at whether a natural marine supplement called NT-II™ can help reduce knee discomfort that happens during physical activity in healthy adults. Many active people experience knee pain when doing things like climbing stairs or walking, even without a specific medical diagnosis like arthritis. This trial will compare NT-II™ (in two different doses: 240 mg and 480 mg) to a common joint supplement, Glucosamine/Chondroitin. The goal is to see if NT-II™, taken once daily for 12 weeks, is more effective at easing this type of knee discomfort. You might be able to join if you are between 20 and 65 years old and have had activity-related knee discomfort for at least three months.

Study design
This is a decentralized, randomized study with three groups, aiming to enroll 120 participants. It compares two doses of NT-II™ to a standard Glucosamine/Chondroitin supplement.
What's involved
You would take a capsule once daily for 12 weeks. The study measures changes in your activity-related knee discomfort from the beginning to the end of this 12-week period.
Compensation
Not stated in the trial record.
Follow-up
The primary measurement of discomfort is taken at 12 weeks, which is the duration of the intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07119645

NT-II™ Collagen for Joint Discomfort and Function

Recruiting
NAAges 20–65InterventionalTreatment
Hofseth Biocare ASA
~120 participants
Updated 2026-05-14 on ClinicalTrials.gov
What's tested:NT-II™ (240 mg)NT-II™ 480 mgGlucosamine/Chondroitin

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in participant-nominated activity-related knee discomfort (VASNA for pain) from baseline to week 12
Measured over Baseline to Week 12

Conditions

Activity-Related Knee Discomfort
Joint Discomfort
Functional Joint Pain
Functional Knee Pain
Knee Acute and Chronic Pain

Explore related trials

Pain of joint of knee

NCT07119645

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Alethios Inc.

    San Francisco, Californiano site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Crawford Head of Medical R&D, MD
[email protected]
+44 7968195497
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults aged 20 to 65 years.
Self-reported, reproducible knee discomfort associated with any knee-loading activities for at least 3 months prior to screening.
Discomfort must occur in at least one knee during a nominated aggravating activity at least twice per week and subside with rest.
VAS rating of 30 mm to 75 mm during the past week for the nominated activity.
No current diagnosis of structural joint disease (e.g., osteoarthritis).
Engages in physical activity involving knee-loading movements at least twice weekly for 20+ minutes.
BMI between 20.0 and 32.5 kg/m².
In good general health with no significant medical comorbidities.
Able and willing to provide informed consent.
Capable of completing study procedures remotely using mobile technology.

Exclusion

Persistent knee pain at rest or recent acute lower-limb trauma.
Diagnosed structural or inflammatory joint disorders.
Current or recent physiotherapy targeting knee pain (within 6 months).
Allergy to fish or any study product ingredients.
Scheduled lower-limb surgery during the study period.
Other musculoskeletal disorders affecting ambulation.
Recent joint injections (within 3 months).
Use of joint supplements in the past 3 months.
Use of analgesics ≥3 days/week in the past 3 months.
NSAIDs/acetaminophen use is permitted with restrictions:
Not within 24 hours of blood sampling or VAS assessments.
Must be documented.
Chronic use of medications that affect musculoskeletal symptoms (e.g., muscle relaxants, gabapentinoids) unless infrequent (≤2x/week) and not within 24 hours of assessments.
Regular use of PPIs (\>3x/week in past month).
Systemic corticosteroids, immunosuppressants, or opioids within 4 weeks.
Unstable weight or significant recent dietary changes.
Significant medical conditions (e.g., cancer, hepatic/renal impairment, CVD, thyroid disease, diabetes).
Neurological, cognitive, or psychiatric disorders affecting participation.
Use of tobacco/nicotine or other substances.
Diagnosed sleep disorders.
Strict vegan diet or sedentary lifestyle.
Inability to swallow capsules.
Pregnant, breastfeeding, or planning pregnancy.
Women of childbearing potential not using contraception.
Participation in another interventional clinical trial.

What this trial measures

  • Change in participant-nominated activity-related knee discomfort (VASNA for pain) from baseline to week 12Baseline to Week 12

    Each participant will identify a specific weight-bearing activity (e.g., stair descent, walking, or squatting) that consistently causes knee discomfort. Pain intensity will be rated on a 100 mm visual analog scale (VAS) for that activity at baseline and again at week 12. The primary outcome is the change in VASNA score from baseline to week 12.